Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.61, while State Street SPDR S&P Biotech ETF trades at $159.46. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| HYG | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $81.32 | $164.28 |
52-Week Low | $78.72 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $79.61, up 0.16% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 paid in August 2026. News highlights bond market volatility amid oil price swings and inflation data, with HYG facing criticism for underperformance versus peers on expenses and yield.
The outlook is cautious due to high-yield bond risks from rising rates and economic uncertainty. Opportunities exist for income seekers, but downside risks are elevated with support at $79. Investors should weigh HYG's liquidity against weaker metrics compared to alternatives.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
